Heart drug trial offers hope for long COVID sufferers
NCT ID NCT05697640
Summary
This study is testing whether a drug called vericiguat, already approved for heart failure, can help people with Long COVID. It aims to see if the drug can improve their ability to do daily activities and reduce severe fatigue. About 104 adults aged 18-50 with Long COVID symptoms for at least 6 months will take either the drug or a placebo pill for 10 weeks to compare results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID ME/CFS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.